Viveve Medical, Inc., a US based medical technology company focused on women's intimate health, has announced that the Taiwan Intellectual Property Office (TIPO) recently issued Taiwan Patent No. 1720358 for Viveve's dual-energy technology device.

The awarded patent further expands and strengthens Viveve's intellectual property portfolio in one of Asia's key markets.

"We are pleased with the issuance of the Taiwanese patent for our dual-energy technology. Taiwan is a key international market for Viveve and plays an important role in influencing women's medical and health trends throughout Asia," said Scott Durbin, Viveve's chief executive officer. "The addition of this newest patent strengthens our intellectual property portfolio, which was recently expanded by a patent issued in South Korea and a U.S. stress urinary incontinence (SUI) patent issued in the fall of 2020. Bolstered by a robust and growing intellectual property estate, we continue to advance our global clinical development and commercialization strategy."

In Taiwan, the Viveve® System is indicated for use in general surgical procedures for anticoagulation and hemostasis. Dynamic Medical Technologies, Inc. remains Viveve's exclusive distribution partner in the country.